Robert J Adelman

CIK 1329161 · last filed 2023-09-21

Robert J Adelman is a corporate insider who has filed 11 SEC Form 4 insider transactions across 5 companies since 2007. The most recent filing, for RYZB, was dated Sep 21, 2023. Across all open-market trades the lifetime net is −$41.0M, making them a net seller over the disclosed history.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$0

Companies

5

Total Filings

11

Lifetime Open-Market Net

-$41.03M

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
RayzeBio, Inc. (RYZB) Delisted 10%+ Owner 4,910,819 $62.49 $306.88M $0 1 2023-09-21
Checkmate Pharmaceuticals, Inc. (CMPI) Delisted 10%+ Owner 2,155,930 $10.50 $22.64M -$6.88M 1 2022-05-17
Metacrine, Inc. (MTCR) Delisted Director 2,443,421 $0.49 $1.21M -$1.65M 2 2021-10-26
Akero Therapeutics, Inc. (AKRO) Delisted 10%+ Owner 3,033,552 $54.65 $165.78M -$35.50M 4 2020-07-06
ARYx Therapeutics, Inc. (ARYX) Delisted Director 3,340,139 $3.00M 3 2008-11-18

Recent Filings

11 filings
Form 4 transactions across all companies, newest first.
Filed Symbol Action Net Shares Net $ Link
2023-09-21 RayzeBio, Inc. (RYZB) Delisted Conv (C) +25,790,810 $0 EDGAR
2022-05-17 Checkmate Pharmaceuticals, Inc. (CMPI) Delisted Sell (S) −658,250 -$6.88M EDGAR
2021-10-26 Metacrine, Inc. (MTCR) Delisted Sell (S) −3,078,510 -$4.64M EDGAR
2020-09-22 Metacrine, Inc. (MTCR) Delisted Mixed +3,059,123 $2.99M EDGAR
2020-07-06 Akero Therapeutics, Inc. (AKRO) Delisted Sell (S) −582,335 -$20.03M EDGAR
2020-02-12 Akero Therapeutics, Inc. (AKRO) Delisted Sell (S) −50,130 -$1.36M EDGAR
2020-02-06 Akero Therapeutics, Inc. (AKRO) Delisted Sell (S) −411,695 -$10.61M EDGAR
2020-01-06 Akero Therapeutics, Inc. (AKRO) Delisted Sell (S) −177,490 -$3.50M EDGAR
2008-11-18 ARYx Therapeutics, Inc. (ARYX) Delisted Buy (P) +1,214,646 $0 EDGAR
2007-11-14 ARYx Therapeutics, Inc. (ARYX) Delisted Mixed +2,125,493 $3.00M EDGAR
Showing 110 of 11
Page 1 of 2
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.